Depuy Synthes Sales INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$30Mgeneral payments (2019-2025)
$0.00research payments (2019-2025)
47,762clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Na $1.6M associated (2023-2025)
- Motoband $1.0M associated (2023-2025)
- Trumatch $403K associated (2023-2025)
- Va-Lcp $280K associated (2023-2025)
- Monovisc $264K associated (2023-2025)
- Attune $244K associated (2023-2025)
- Orthovisc $230K associated (2023-2025)
- Tfn-Advance $222K associated (2023-2025)
- Velys $202K associated (2023-2025)
- Lcp $191K associated (2023-2025)
- Teligen $181K associated (2023-2025)
- Matrixmandible $156K associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Bryan Den Hartog | Stillwater, MN | Orthopaedic Surgery | $6,945,819.48 |
| Edwin Goble | Logan, UT | Orthopaedic Surgery | $1,058,599.02 |
| Johannes Coetzee | Edina, MN | Foot and Ankle Surgery | $1,009,692.92 |
| Jeffrey Johnson | Saint Louis, MO | Foot and Ankle Surgery | $918,367.33 |
| Craig Breslauer | Stuart, FL | Foot & Ankle Surgery | $847,509.01 |
| Phinit Phisitkul | Sioux City, IA | Foot and Ankle Surgery | $839,211.11 |
| Babak Baravarian | Santa Monica, CA | Podiatrist | $836,946.14 |
| David Lowenberg | San Francisco, CA | Orthopaedic Trauma | $774,558.00 |
| John Anderson | Alamogordo, NM | Podiatrist | $729,548.04 |
| Virak Tan | Newark, NJ | Hand Surgery | $706,005.63 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.